Karthik Chetlapalli
About
Copy Link
Biography
Karthik is currently a Yale medical student, having had diverse experiences across medicine and biotech. He began his career at the University of Southern California in Los Angeles. While an undergrad, he worked as a synaptic electrophysiology research assistant, an ambulance EMT, and a vice president for a student-run veteran’s rehabilitation organization. Later as a business development intern for Neurocrine Biosciences, he screened academic institutes and upcoming startups for novel neuropsychiatric therapeutics.
During his Master’s, Karthik explored the prospect of new stem-cell-based methods for use in antifibrotics and next-generation (CAR) cell therapy. While he worked as a lab assistant for kidney organoid research at USC, Karthik started and led his non-profit SROA to tackle stem cell treatment fraud. More recently, Karthik worked at City of Hope as a clinical genetics assistant, supporting genetic counseling and precision medicine for patients facing cancer. As a current medical student, Karthik is interested in clinical trial equity, cancer outcomes, immuno-oncology therapeutics, and the power of venture capital in advancing medicine.
Karthik earned an M.S. in Stem Cell Biology and a B.S. in Neuroscience with a minor in Health Care Studies from the University of Southern California.
Education & Training
- MS
- University of Southern California, Stem Cell Biology
- BS
- University of Southern California, Neuroscience (2021)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Harlan Krumholz, MD, SM
Satoko Ito, MD, PhD
Alfred Lee, MD, PhD
George Goshua, MD, SM, FACP
Kunal Potnis, MD
Lakshmanan Krishnamurti, MD
Publications
2026
Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis
Chetlapalli K, Ito S, Ng DQ, Sra MS, Wang D, Krumholz H, Krishnamurti L, Pandya A, Goshua G. Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis. Blood Journal 2026, blood.2025032290. DOI: 10.1182/blood.2025032290.Peer-Reviewed Original ResearchThis study investigates the cost-effectiveness of haploidentical stem cell transplantation, gene therapy, and standard care for sickle cell disease, showing transplantation offers the best value globally.
2024
Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchCitationsAltmetricConceptsStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcome
News
Copy Link